NR3C2 and hypertensive disorder: Optimizing the three-drug regimen, switching to a more potent diuretic, adding a mineralocorticoid receptor antagonist as the fourth drug, a β-blocker or combined α- and β-blocker as the fifth drug and an α1-blocker or a peripheral vasodilator as a final option when failing to achieve target BP values, are current recommendations that regard the correct management of R-HTN.